Myriad Genetics, SOPHiA GENETICS partner to advance prostate cancer genomic instability score technology

Bitget2026/10/08 13:01

Myriad Genetics formed a collaboration with SOPHiA GENETICS to advance a prostate cancer genomic instability score, PrGIS, with AstraZeneca. Partnership targets clinical-trial use of PrGIS for patient stratification, supporting potential companion diagnostic development for precision oncology medicines. Myriad’s MyChoice CDx test will generate the PrGIS score, expanding the assay beyond its current ovarian cancer companion diagnostic use. SOPHiA will integrate PrGIS into its decentralized solid-tumor HRD solution, aiming to broaden global access through its cloud laboratory network. Myriad plans to present PrGIS research co-authored with AstraZeneca at ESMO Congress 2026, supporting biomarker validation. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myriad Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080900PRIMZONEFULLFEED9841962) on October 08, 2026, and is solely responsible for the information contained therein.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Myriad Genetics formed a collaboration with SOPHiA GENETICS to advance a prostate cancer genomic instability score, PrGIS, with AstraZeneca.
Partnership targets clinical-trial use of PrGIS for patient stratification, supporting potential companion diagnostic development for precision oncology medicines.
Myriad’s MyChoice CDx test will generate the PrGIS score, expanding the assay beyond its current ovarian cancer companion diagnostic use.
SOPHiA will integrate PrGIS into its decentralized solid-tumor HRD solution, aiming to broaden global access through its cloud laboratory network.
Myriad plans to present PrGIS research co-authored with AstraZeneca at ESMO Congress 2026, supporting biomarker validation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myriad Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080900PRIMZONEFULLFEED9841962) on October 08, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Myriad Genetics, SOPHiA GENETICS partner to advance prostate cancer genomic instability score technology

You may also like

Crypto prices